Working… Menu

Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04969887
Recruitment Status : Recruiting
First Posted : July 21, 2021
Last Update Posted : October 6, 2021
Bristol-Myers Squibb
Information provided by (Responsible Party):
Olivia Newton-John Cancer Research Institute

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 1, 2024
Estimated Study Completion Date : December 2024